REDITREX Drug Patent Profile
✉ Email this page to a colleague
When do Reditrex patents expire, and when can generic versions of Reditrex launch?
Reditrex is a drug marketed by Nordic Grp and is included in one NDA.
The generic ingredient in REDITREX is methotrexate. There are twenty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REDITREX?
- What are the global sales for REDITREX?
- What is Average Wholesale Price for REDITREX?
Summary for REDITREX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 137 |
| Patent Applications: | 4,343 |
| Drug Prices: | Drug price information for REDITREX |
| What excipients (inactive ingredients) are in REDITREX? | REDITREX excipients list |
| DailyMed Link: | REDITREX at DailyMed |
US Patents and Regulatory Information for REDITREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nordic Grp | REDITREX | methotrexate | SOLUTION;SUBCUTANEOUS | 210737-001 | Nov 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nordic Grp | REDITREX | methotrexate | SOLUTION;SUBCUTANEOUS | 210737-007 | Nov 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nordic Grp | REDITREX | methotrexate | SOLUTION;SUBCUTANEOUS | 210737-004 | Nov 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nordic Grp | REDITREX | methotrexate | SOLUTION;SUBCUTANEOUS | 210737-008 | Nov 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nordic Grp | REDITREX | methotrexate | SOLUTION;SUBCUTANEOUS | 210737-002 | Nov 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nordic Grp | REDITREX | methotrexate | SOLUTION;SUBCUTANEOUS | 210737-003 | Nov 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nordic Grp | REDITREX | methotrexate | SOLUTION;SUBCUTANEOUS | 210737-006 | Nov 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for REDITREX
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Nordic Group B.V. | Nordimet | methotrexate | EMEA/H/C/003983 Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate. |
Authorised | no | no | no | 2016-08-18 | |
| Therakind (Europe) Limited | Jylamvo | methotrexate | EMEA/H/C/003756 In rheumatological and dermatological diseasesActive rheumatoid arthritis in adult patients.Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.In oncologyMaintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over. |
Authorised | no | no | no | 2017-03-29 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
